A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function

Inclusion criteria

• Adult patients, >/= 18 years of age
• Histologically or cytologically documented invasive metastatic breast cancer
• Human epidermal growth factor receptor 2 (HER2) -positive disease
• Adequate bone marrow and organ function (other than hepatic dysfunction allowed by protocol)
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Left ventricular ejection fraction >/=50%
• Normal hepatic function, or mild to moderate hepatic impairment (Child-Pugh Class A or B)

Exclusion criteria

• History of Grade >/=3 infusion reaction, hypersensitivity reaction, or pneumonitis in response to trastuzumab
• Investigational therapy or any other anticancer therapy </=28 days before first study treatment
• Previous treatment with trastuzumab emtansine
• Brain metastases that are untreated or symptomatic or require therapy to control symptoms or any radiation, surgery or other therapy to control symptoms from brain metastases within 1 month of the first study treatment
• History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or other cancers with a similar outcome as those mentioned above
• Current peripheral neuropathy of Grade >/=2
• Child-Pugh Class C hepatic impairment
• Encephalopathy >/= Grade 2
• For patients with normal hepatic function: history of drug or alcohol addiction or history of hepatitis B and/or hepatitis C
• Active hepatitis A, B and/or C
• Current unstable ventricular arrhythmia requiring treatment
• History of symptomatic CHF (NYHA Classes II-IV)
• History of myocardial infarction or unstable angina within 6 months of enrollment
• History of a decrease in LVEF to<40% or symptomatic CHF with previous trastuzumab treatment
• Pregnant or lactating women
• Known HIV infection